Shares of DEST stock traded down GBX 2.90 ($0.04) during mid-day trading on Thursday, hitting GBX 126.10 ($1.78). The stock had a trading volume of 13,000 shares, compared to its average volume of 4,205. Destiny Pharma has a fifty-two week low of GBX 111 ($1.57) and a fifty-two week high of GBX 235 ($3.32).
Destiny Pharma (LON:DEST) last announced its quarterly earnings data on Thursday, April 12th. The company reported GBX (8.40) (($0.12)) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of GBX (8.30) (($0.12)) by GBX (0.10) ($0.00).
About Destiny Pharma
Destiny Pharma plc, a biotechnology company, focuses on the development of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections.
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.